Loading...
Loading...
Predicts the risk of clinically relevant bleeding in patients with venous thromboembolism (DVT/PE) on anticoagulation therapy. VTE-BLEED was developed to identify patients at increased bleeding risk for whom extended anticoagulation carries higher risk/benefit uncertainty, and to support shared decision-making about duration of anticoagulation therapy.
Active Cancer (Non-Skin, Treated within 6 Months)
Male Patient with Uncontrolled Hypertension (SBP ≥ 140 mmHg)
Anemia (Hgb < 130 g/L for Men, < 120 g/L for Women)
History of GI Bleeding
Renal Insufficiency (CrCl < 60 mL/min)
Awaiting input
Fill in the parameters to see your result